AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9564391 — intervention group
Group type: EXPERIMENTAL
Intervention: Tunnelled group
Number of subjects: 213
Study 9564391 — intervention group
Group type: COMPARATOR
Intervention: Standard group
Number of subjects: 213
Study 1525604 — intervention group
Group type: EXPERIMENTAL
Intervention: Splenic irradiation (SI+)
Number of subjects: 239
Study 1525604 — intervention group
Group type: COMPARATOR
Intervention: No splenic irradiation (SI‐)
Number of subjects: 239
Study 1525604 — intervention group
Group type: EXPERIMENTAL
Intervention: Both SI+ and SI‐
Number of subjects: 239
Study 4025206 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryptophan
Number of subjects: 20
Study 4025206 — intervention group
Group type: EXPERIMENTAL
Intervention: Tyrosine
Number of subjects: 20
Study 4025206 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 29409289 — intervention group
Group type: EXPERIMENTAL
Intervention: Suture-tape augmentation
Number of subjects: 60
Study 29409289 — intervention group
Group type: COMPARATOR
Intervention: Modified Broström procedure
Number of subjects: 60
Study 28601497 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-monthly paliperidone palmitate (PP1M)
Number of subjects: 130
Study 28601497 — intervention group
Group type: COMPARATOR
Intervention: Daily oral antipsychotics
Number of subjects: 130
Study 26800231 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib 8 mg
Number of subjects: 271
Study 26800231 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib 10 mg
Number of subjects: 271
Study 26800231 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 271
Study 26800231 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib (all doses except 2 mg)
Number of subjects: 271
Study 26800231 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib 8 mg and 10 mg
Number of subjects: 271
Study 26800231 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib (all doses)
Number of subjects: 271
Study 24189107 — intervention group
Group type: EXPERIMENTAL
Intervention: Latent MTPs
Number of subjects: 15
Study 24189107 — intervention group
Group type: COMPARATOR
Intervention: Non-MTPs
Number of subjects: 15
Study 22451206 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of liquefied brain tissue (5 days per week)
Number of subjects: 0
Study 22451206 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposed mice
Number of subjects: 0
Study 22451206 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients and exposed mice
Number of subjects: 0
Study 20637202 — intervention group
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a alone
Number of subjects: 1343
Study 20637202 — intervention group
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a with ribavirin
Number of subjects: 1343
Study 20637202 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 1343
Study 17444589 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab 3 mg/kg plus MTX
Number of subjects: 70
Study 17444589 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab 6 mg/kg plus MTX
Number of subjects: 70
Study 17444589 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus MTX
Number of subjects: 70
Study 14725717 — intervention group
Group type: EXPERIMENTAL
Intervention: AIOS 24-hour
Number of subjects: 620
Study 14725717 — intervention group
Group type: EXPERIMENTAL
Intervention: AIOS 1-month
Number of subjects: 620
Study 14725717 — intervention group
Group type: EXPERIMENTAL
Intervention: AIOS scores
Number of subjects: 620
Study 12411835 — intervention group
Group type: EXPERIMENTAL
Intervention: Sestamibi scintimammography
Number of subjects: 73
Study 12411835 — intervention group
Group type: COMPARATOR
Intervention: Mammography
Number of subjects: 73
Study 12411835 — intervention group
Group type: EXPERIMENTAL
Intervention: Mammography + Sestamibi scintimammography
Number of subjects: 73
Study 9812075 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous nitroglycerin
Number of subjects: 24
Study 9812075 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 7753339 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (125 micrograms/kg) and AVP (10 units) combined administration
Number of subjects: 7
Study 7753339 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg) with naloxone and AVP
Number of subjects: 7
Study 7753339 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 2396618 — intervention group
Group type: EXPERIMENTAL
Intervention: Gowning group (102 infants)
Number of subjects: 202
Study 2396618 — intervention group
Group type: COMPARATOR
Intervention: Nongowning group (100 infants)
Number of subjects: 202
Study 2396618 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 202
Study 7384169 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose-1,6-diphosphate (FDP)
Number of subjects: 30
Study 7384169 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose
Number of subjects: 30
Study 7384169 — intervention group
Group type: COMPARATOR
Intervention: Physiological saline
Number of subjects: 30
Study 31433953 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet with DCAD of 0 mEq/kg DM
Number of subjects: 8
Study 31433953 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet with DCAD of -40 mEq/kg DM
Number of subjects: 8
Study 31433953 — intervention group
Group type: COMPARATOR
Intervention: Control diet with DCAD of 85 mEq/kg DM
Number of subjects: 8
Study 31337172 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-Hz rTMS
Number of subjects: 60
Study 31337172 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-Hz rTMS
Number of subjects: 60
Study 31337172 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 60
Study 27053335 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane (1‐8% in oxygen by face mask)
Number of subjects: 21
Study 27053335 — intervention group
Group type: COMPARATOR
Intervention: Thiopental sodium (25 mg/kg administered rectally)
Number of subjects: 21
Study 26141305 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-dose combination of r-hFSH plus r-hLH (Pergoveris)
Number of subjects: 946
Study 26141305 — intervention group
Group type: COMPARATOR
Intervention: r-hFSH monotherapy (GONAL-f)
Number of subjects: 946
Study 23358057 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive text messages delivered twice daily for three months
Number of subjects: 26
Study 21333087 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil infusion during pressure support ventilation
Number of subjects: 14
Study 21333087 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil infusion
Number of subjects: 14
Study 21333087 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion during pressure support ventilation
Number of subjects: 14
Study 19296179 — intervention group
Group type: EXPERIMENTAL
Intervention: SEE IT intervention
Number of subjects: 64
Study 19296179 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 64
Study 17122228 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated external defibrillators (AED) under the influence of electromagnetic fields (EMF)
Number of subjects: 390
Study 15606399 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrase MT12 (12,000 lipase units per capsule)
Number of subjects: 0
Study 15606399 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrase MT20 (20,000 lipase units per capsule)
Number of subjects: 0
Study 15606399 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11416689 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of low-dose aspirin, calcium, or other dietary supplements for the prevention of pre-eclampsia
Number of subjects: 0
Study 11416689 — intervention group
Group type: EXPERIMENTAL
Intervention: Management considerations for chronic hypertension and pregnancy-specific conditions
Number of subjects: 0
Study 11416689 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of K5 for determining diastolic pressure
Number of subjects: 0
Study 11416689 — intervention group
Group type: EXPERIMENTAL
Intervention: Elimination of edema as a criterion for diagnosing pre-eclampsia
Number of subjects: 0
Study 11416689 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure increases of 30 mm Hg systolic or 15 mm Hg diastolic as a diagnostic criterion
Number of subjects: 0
Study 9135770 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrantel
Number of subjects: 330
Study 9135770 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole
Number of subjects: 330
Study 9135770 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 330
Study 7983226 — intervention group
Group type: EXPERIMENTAL
Intervention: Desensitization treatment to lessen dietary restraint anxiety
Number of subjects: 49
Study 7983226 — intervention group
Group type: COMPARATOR
Intervention: Relaxation training (control group)
Number of subjects: 49
Study 2607227 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical spine rotation during leg length measurement
Number of subjects: 0
Study 2607227 — intervention group
Group type: EXPERIMENTAL
Intervention: Flat and hi-low tables during leg length measurement
Number of subjects: 0
Study 2607227 — intervention group
Group type: EXPERIMENTAL
Intervention: Galvanic paravertebral muscle stimulation during leg length measurement
Number of subjects: 0
Study 2607227 — intervention group
Group type: COMPARATOR
Intervention: Cervically lesioned subjects
Number of subjects: 0
Study 2607227 — intervention group
Group type: EXPERIMENTAL
Intervention: Interrater and intrarater reliability measurements
Number of subjects: 0
Study 31660848 — intervention group
Group type: EXPERIMENTAL
Intervention: Bi-clustering tree ensembles
Number of subjects: 0
Study 31660848 — intervention group
Group type: COMPARATOR
Intervention: Traditional tree-ensemble methods (ERT and RF)
Number of subjects: 0
Study 28475737 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Number of subjects: 787
Study 26004162 — intervention group
Group type: EXPERIMENTAL
Intervention: Goserelin (GnRHa) 3.6 mg implant
Number of subjects: 63
Study 26004162 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 23615868 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanfacine extended release (GXR) 4 mg
Number of subjects: 42
Study 23615868 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX) 50 mg
Number of subjects: 42
Study 23615868 — intervention group
Group type: EXPERIMENTAL
Intervention: GXR and LDX in combination
Number of subjects: 42
Study 23615868 — intervention group
Group type: COMPARATOR
Intervention: Control (GXR or LDX alone)
Number of subjects: 42
Study 21853822 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacists attending consultant-led ward rounds in addition to providing a ward pharmacy service
Number of subjects: 5
Study 21853822 — intervention group
Group type: COMPARATOR
Intervention: Pharmacists providing a ward pharmacy service alone
Number of subjects: 5
Study 19953774 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-step etch&rinse adhesive system (Single Bond, 3M ESPE)
Number of subjects: 33
Study 19953774 — intervention group
Group type: COMPARATOR
Intervention: Two-step self-etch adhesive (Clearfil SE Bond, Kuraray)
Number of subjects: 33
Study 17111469 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal hyperbaric ropivacaine 10.5 mg
Number of subjects: 60
Study 17111469 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal hyperbaric ropivacaine 12 mg
Number of subjects: 60
Study 17111469 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal hyperbaric ropivacaine 13.5 mg
Number of subjects: 60
Study 17111469 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal hyperbaric ropivacaine 15 mg
Number of subjects: 60
Study 15575447 — intervention group
Group type: EXPERIMENTAL
Intervention: AmF toothpaste (1250 ppm F‐) plus AmF mouthrinse (250 ppm F‐)
Number of subjects: 84
Study 15575447 — intervention group
Group type: COMPARATOR
Intervention: Sodium monofluorophosphate dentifrice (1250 ppm F‐)
Number of subjects: 84
Study 15575447 — intervention group
Group type: COMPARATOR
Intervention: AmF dentifrice (1250 ppm F‐)
Number of subjects: 84
Study 15575447 — intervention group
Group type: COMPARATOR
Intervention: NaMFP toothpaste (1250 ppm F‐) plus NaMFP varnish (1250 ppm)
Number of subjects: 84
Study 11182337 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant estramustine (10 mg/kg/day) and etoposide (50 mg/m2/day) for three cycles, followed by radical prostatectomy.
Number of subjects: 18
Study 11182337 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant estramustine and etoposide treatment.
Number of subjects: 18
Study 11182337 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant estramustine and etoposide treatment followed by radical prostatectomy.
Number of subjects: 18
Study 9216132 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-loop drug infusion using arbutamine
Number of subjects: 0
Study 9216132 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated delivery of arbutamine
Number of subjects: 0
Study 7965851 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal exercise
Number of subjects: 8
Study 7965851 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate exercise
Number of subjects: 8
Study 7965851 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal exercise
Number of subjects: 8
Study 7965851 — intervention group
Group type: COMPARATOR
Intervention: Control (sitting on a bicycle)
Number of subjects: 8
Study 3524307 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 300 mg orally and metoclopramide 10 mg intravenously
Number of subjects: 0
Study 3524307 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 300 mg orally and metoclopramide 20 mg intravenously
Number of subjects: 0
Study 3524307 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine alone
Number of subjects: 0
Study 3524307 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29725868 — intervention group
Group type: EXPERIMENTAL
Intervention: velmanase alfa
Number of subjects: 33
Study 27093976 — intervention group
Group type: EXPERIMENTAL
Intervention: Pixantrone 50 mg/m(2) intravenously combined with rituximab 375 mg/m(2) intravenously on day 1, for up to six cycles.
Number of subjects: 0
Study 27093976 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine 1000 mg/m(2) intravenously combined with rituximab 375 mg/m(2) intravenously on day 1, for up to six cycles.
Number of subjects: 0
Study 25672163 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium polystyrene sulphonate (CPS)
Number of subjects: 97
Study 25672163 — intervention group
Group type: COMPARATOR
Intervention: Sodium polystyrene sulphonate (SPS)
Number of subjects: 97
Study 23325717 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive Recovery (PR) for 25-s duration
Number of subjects: 8
Study 23325717 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive Recovery (PR) for 50-s duration
Number of subjects: 8
Study 23325717 — intervention group
Group type: COMPARATOR
Intervention: Active Recovery (AR) for 25-s duration
Number of subjects: 8
Study 23325717 — intervention group
Group type: COMPARATOR
Intervention: Active Recovery (AR) for 50-s duration
Number of subjects: 8
Study 23325717 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive Recovery (PR) for 100-s duration
Number of subjects: 8
Study 23325717 — intervention group
Group type: COMPARATOR
Intervention: Active Recovery (AR) for 100-s duration
Number of subjects: 8
Study 23325717 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive Recovery (PR) for 25-s and 50-s durations
Number of subjects: 8
Study 23325717 — intervention group
Group type: COMPARATOR
Intervention: Active Recovery (AR) for 25-s and 50-s durations
Number of subjects: 8
Study 21875410 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium treatment
Number of subjects: 0
Study 18194522 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led intervention involving extended training in risk assessment, risk communication, decision aid, and motivational interviewing; 2 consultations and 1 follow-up telephone call.
Number of subjects: 720
Study 18194522 — intervention group
Group type: COMPARATOR
Intervention: Usual care by nurses in the control arm after risk estimation according to the national guideline.
Number of subjects: 720
Study 16484111 — intervention group
Group type: EXPERIMENTAL
Intervention: Relational condition (apprehended as lying on the other member)
Number of subjects: 0
Study 16484111 — intervention group
Group type: COMPARATOR
Intervention: Independent condition (apprehended as independent objects)
Number of subjects: 0
Study 12938827 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 10 mg at bedtime
Number of subjects: 14
Study 10732179 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-aided treatment (high technology)
Number of subjects: 47
Study 10732179 — intervention group
Group type: COMPARATOR
Intervention: Traditional brush machine treatment (low technology)
Number of subjects: 47
Study 8617896 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance training
Number of subjects: 110
Study 8617896 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training
Number of subjects: 110
Study 8617896 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi maintenance
Number of subjects: 110
Study 1633517 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous ascites filtration
Number of subjects: 35
Study 1633517 — intervention group
Group type: COMPARATOR
Intervention: Total paracentesis plus intravenous albumin infusion
Number of subjects: 35
Study 6367811 — intervention group
Group type: EXPERIMENTAL
Intervention: clenbuterol
Number of subjects: 39
Study 6367811 — intervention group
Group type: COMPARATOR
Intervention: flavoxate hydrochloride
Number of subjects: 39
Study 31783136 — intervention group
Group type: EXPERIMENTAL
Intervention: Sheng-Hua-Tang (SHT) 200 mg/kg orally for seven consecutive days
Number of subjects: 0
Study 31783136 — intervention group
Group type: EXPERIMENTAL
Intervention: Sheng-Hua-Tang (SHT)
Number of subjects: 0
Study 31751400 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based action teams to change social norms on gender and violence; specific dosage and duration not mentioned.
Number of subjects: 0
Study 28903842 — intervention group
Group type: EXPERIMENTAL
Intervention: ≤3 Mets of physical activity (chest physiotherapy, sitting over edge of bed, standing and sitting on chair at bedside) on zero postoperative day
Number of subjects: 174
Study 28903842 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment on first postoperative day
Number of subjects: 174
Study 25649209 — intervention group
Group type: EXPERIMENTAL
Intervention: QMF149 (indacaterol maleate 500 µg/MF 400 µg)
Number of subjects: 1519
Study 25649209 — intervention group
Group type: COMPARATOR
Intervention: MF (400 µg)
Number of subjects: 1519
Study 25059121 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive web-based intervention including Healthy Heart Profile and calorie restricted diet
Number of subjects: 160
Study 25059121 — intervention group
Group type: COMPARATOR
Intervention: Standard information on dietary intake and physical activity via the study website
Number of subjects: 160
Study 22584133 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin suspension activated by the LGS function
Number of subjects: 3128
Study 19520247 — intervention group
Group type: EXPERIMENTAL
Intervention: Various interventions used in randomized clinical trials for AHFS
Number of subjects: 0
Study 19520247 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 17383995 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous dopamine (5 microg/kg/min)
Number of subjects: 12
Study 17383995 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous dopamine (10 microg/kg/min)
Number of subjects: 12
Study 17383995 — intervention group
Group type: COMPARATOR
Intervention: Control (no dopamine)
Number of subjects: 12
Study 15555218 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg zoledronic acid
Number of subjects: 507
Study 15555218 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 507
Study 11768276 — intervention group
Group type: EXPERIMENTAL
Intervention: Individually tailored treatment (n = 38)
Number of subjects: 116
Study 11768276 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Chinese herbal formulation (n = 43)
Number of subjects: 116
Study 11768276 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 35)
Number of subjects: 116
Study 9513798 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary Closed Angle Glaucoma (PCAG) subjects
Number of subjects: 0
Study 9513798 — intervention group
Group type: COMPARATOR
Intervention: Control group of normal subjects
Number of subjects: 0
Study 8067219 — intervention group
Group type: EXPERIMENTAL
Intervention: Solcotrans
Number of subjects: 50
Study 8067219 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 50
Study 3231285 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery within 72 hours post subarachnoid hemorrhage (SAB)
Number of subjects: 115
Study 3231285 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery at later intervals
Number of subjects: 115
Study 3231285 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall surgical treatment
Number of subjects: 115
Study 31291977 — intervention group
Group type: EXPERIMENTAL
Intervention: jin acupuncture group
Number of subjects: 166
Study 31291977 — intervention group
Group type: COMPARATOR
Intervention: pseudo acupuncture group
Number of subjects: 166
Study 29107679 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective internal radiotherapy (SIRT) with yttrium-90 resin microspheres
Number of subjects: 467
Study 29107679 — intervention group
Group type: COMPARATOR
Intervention: Sorafenib (400 mg twice daily)
Number of subjects: 467
Study 25321951 — intervention group
Group type: EXPERIMENTAL
Intervention: Wavefront-guided (WFG) PRK treatment
Number of subjects: 71
Study 25321951 — intervention group
Group type: EXPERIMENTAL
Intervention: Wavefront-optimized (WFO) PRK treatment
Number of subjects: 71
Study 22716199 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-centered collaborative care (CC)
Number of subjects: 132
Study 22716199 — intervention group
Group type: COMPARATOR
Intervention: Standard collaborative care (CC)
Number of subjects: 132
Study 21480032 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive intervention (FRIENDS program, cognitive-behavioral anxiety intervention)
Number of subjects: 98